Isabell Witzel

4.5k total citations · 1 hit paper
115 papers, 2.5k citations indexed

About

Isabell Witzel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Isabell Witzel has authored 115 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 40 papers in Pulmonary and Respiratory Medicine and 31 papers in Cancer Research. Recurrent topics in Isabell Witzel's work include Brain Metastases and Treatment (29 papers), HER2/EGFR in Cancer Research (25 papers) and Lung Cancer Research Studies (20 papers). Isabell Witzel is often cited by papers focused on Brain Metastases and Treatment (29 papers), HER2/EGFR in Cancer Research (25 papers) and Lung Cancer Research Studies (20 papers). Isabell Witzel collaborates with scholars based in Germany, Switzerland and United States. Isabell Witzel's co-authors include Volkmar Müller, Klaus Pantel, Leticia Oliveira‐Ferrer, Karin Milde‐Langosch, Harriet Wikman, F. Jänicke, Ralph M. Wirtz, Thomas Karn, Elena Laakmann and Nadia Harbeck and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Isabell Witzel

108 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

2021 330 citations Isabell Witzel, Nadia Harbeck et al. profile →

Peers

Isabell Witzel

ONCOL

PRM

IMMUN

Jean‐Sébastien Frenel France

Paula R. Pohlmann United States

Hyo S. Han United States

Kevin Punie Belgium

J.C. Soria France

Thomas Bachelot France

Christian Schem Germany

Philippe Aftimos Belgium

Alessandro Marco Minisini Italy

Amy E. McKee United States

Jean‐Sébastien Frenel France

Isabell Witzel

1.4k ×0.9

ONCOL

809 ×1.0

PRM

708 ×1.0

801 ×1.2

350 ×1.1

IMMUN

Citations per year, relative to Isabell Witzel Isabell Witzel (= 1×) peers Jean‐Sébastien Frenel

Countries citing papers authored by Isabell Witzel

Since Specialization

Citations

This map shows the geographic impact of Isabell Witzel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabell Witzel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabell Witzel more than expected).

Fields of papers citing papers by Isabell Witzel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabell Witzel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabell Witzel. The network helps show where Isabell Witzel may publish in the future.

Co-authorship network of co-authors of Isabell Witzel

This figure shows the co-authorship network connecting the top 25 collaborators of Isabell Witzel. A scholar is included among the top collaborators of Isabell Witzel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabell Witzel. Isabell Witzel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Legler, Karen, Thomas Karn, Serenella Eppenberger‐Castori, et al.. (2023). The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients. Cancer Cell International. 23(1). 47–47. 4 indexed citations

Saygı, Ceren, Karen Legler, Christian Gorzelanny, et al.. (2022). Insights into the Steps of Breast Cancer–Brain Metastases Development: Tumor Cell Interactions with the Blood–Brain Barrier. International Journal of Molecular Sciences. 23(3). 1900–1900. 8 indexed citations

Speiser, Dorothee, et al.. (2022). Paradigmatic Approach to Support Personalized Counseling With Digital Health (iKNOW). JMIR Formative Research. 7. e41179–e41179. 6 indexed citations

Anders, Sven, Benjamin Ondruschka, Hans O. Pinnschmidt, et al.. (2022). Frequency of Injuries to Women after Sexual Offense – Relevance of a Gynecology Examination. Geburtshilfe und Frauenheilkunde. 82(4). 420–426. 1 indexed citations

Laakmann, Elena, Tjoung‐Won Park‐Simon, Rudolf Weide, et al.. (2022). Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC Registry. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 19(2). e34–e35. 1 indexed citations

Schmalfeldt, Barbara, Volkmar Müller, Linn Wölber, et al.. (2021). MUC5AC expression is linked to mucinous/endometroid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. Pathology - Research and Practice. 224. 153533–153533. 3 indexed citations

Eulenburg, Christine zu, Sabine Behrens, Barbara Schmalfeldt, et al.. (2020). The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study. The Breast. 55. 98–104. 12 indexed citations

Banys-Paluchowski, Malgorzata, Isabell Witzel, Bahriye Aktas, et al.. (2019). The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. Scientific Reports. 9(1). 2318–2318. 27 indexed citations

Banys-Paluchowski, Malgorzata, Isabell Witzel, Sabine Riethdorf, et al.. (2017). Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. Anticancer Research. 37(6). 3117–3128. 17 indexed citations

10.

Milde‐Langosch, Karin, Leticia Oliveira‐Ferrer, Harriet Wikman, et al.. (2015). Relevance of βGal–βGalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients. Breast Cancer Research and Treatment. 151(3). 515–528. 30 indexed citations

11.

Mueller, Volkmar, Elena Laakmann, Tanja Fehm, et al.. (2015). Brain Metastases in Breast Cancer Network Germany (BMBC; GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from patients with brain metastases.. Journal of Clinical Oncology. 33. 5 indexed citations

12.

Oliveira‐Ferrer, Leticia, Isabell Witzel, Thomas Karn, et al.. (2015). Relevance of glycosylation-associated genes for tumor progression and metastasis localization in breast cancer. Annals of Oncology. 26. iii15–iii15. 1 indexed citations

13.

Mahner, Sven�, Linn Woelber, Volkmar Mueller, et al.. (2015). Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. Frontiers in Oncology. 5. 211–211. 18 indexed citations

14.

Witzel, Isabell, Volkmar Müller, Wolfgang Abenhardt, et al.. (2014). Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry. BMC Cancer. 14(1). 806–806. 31 indexed citations

15.

Wikman, Harriet, Sirkku Pollari, Markus Glatzel, et al.. (2014). Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. Oncotarget. 5(10). 3076–3087. 32 indexed citations

16.

Witzel, Isabell, Monika Graeser, Thomas Karn, et al.. (2013). Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. Journal of Cancer Research and Clinical Oncology. 139(5). 809–816. 30 indexed citations

17.

Milde‐Langosch, Karin, Thomas Karn, Volkmar Müller, et al.. (2012). Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Research and Treatment. 137(1). 57–67. 62 indexed citations

18.

Witzel, Isabell, Eva Johanna Kantelhardt, Karin Milde‐Langosch, et al.. (2011). Management of Patients with Brain Metastases Receiving Trastuzumab Treatment for Metastatic Breast Cancer. Onkologie. 34(6). 304–308. 19 indexed citations

19.

Ihnen, Maike, Karin Milde‐Langosch, Sylvia Höller, et al.. (2010). Expression levels of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) in primary breast carcinoma and distant breast cancer metastases.. SHILAP Revista de lepidopterología. 28(2). 71–8. 15 indexed citations

20.

Witzel, Isabell, Christoph Thomssen, Waldemar Wilczak, et al.. (2006). Clinical Utility of Determination of HER-2/neu and EGFR Fragments in Serum of Patients with Metastatic Breast Cancer. The International Journal of Biological Markers. 21(3). 131–140. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact